Positive
●
Proactive Investors
●
about 2 months ago
Citi has raised its price target on Novo Nordisk (NYSE:NVO) to DKK330 ahead of second-quarter results on 5 August, citing the strength of the Danish drugmaker's Wegovy pill launch. The broker lifted its 2026 sales and operating income estimates by 4% to 5%, and its earnings per share forecasts for 2027 to 2030 by around 7%, on currency movements and stronger second-quarter Wegovy trends.